|Bid||37.13 x 800|
|Ask||39.00 x 900|
|Day's Range||37.40 - 38.29|
|52 Week Range||25.80 - 52.19|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.93|
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi’s 16th Annual BioPharma Virtual Conference, September 8 - 10, 2021 Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one inv